US2019211079A1PendingUtilityA1

Engineered heterodimeric protein domains

Assignee: MERCK PATENT GMBHPriority: Mar 24, 2006Filed: Dec 12, 2018Published: Jul 11, 2019
Est. expiryMar 24, 2026(expired)· nominal 20-yr term from priority
C07K 16/468C07K 2317/526C07K 16/246C07K 2317/21C07K 16/00C07K 2317/31C07K 2319/30C07K 2317/52C07K 2317/524C07K 2319/00
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides an engineered multidomain protein including at least two nonidentical engineered domains, each of which contains a protein-protein interaction interface containing amino acid sequence segments derived from two or more existing homologous parent domains, thereby conferring on the engineered domains assembly specificities distinct from assembly specificities of the parent domains. In particular, the engineered domains form heterodimers with one another preferentially over forming homodimers. Methods of designing and using the engineered proteins are also included.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 16 . (canceled) 
     
     
         17 . A method of colocalizing bio-active domains when administered to a biological system, the method comprising the step of administering to the biological system a multimeric protein comprising at least first and second nonidentical engineered domains, each of the first and second engineered domains containing a protein-protein interaction interface comprising amino acid sequence segments derived from two or more naturally occurring homologous parent domains, thereby conferring on said first and second engineered domains assembly specificities distinct from assembly specificities of the parent domains, wherein the first and second engineered domains form heterodimers with one another preferentially over forming homodimers, wherein the multidomain protein comprises a first bio-active domain comprising an antibody variable domain, and wherein the multidomain protein further comprises a second bio-active domain comprising a second antibody variable domain with distinct specificity. 
     
     
         18 . The method of  claim 17 , wherein the biological system is a mammal. 
     
     
         19 - 35 . (canceled)

Join the waitlist — get patent alerts

Track US2019211079A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.